---
schema_version: "secwatch.filing_event.v1"
accession: "0001665988-25-000025"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:39:03.038858+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M

## Summary
- GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.
- Non-GAAP EPS $0.15, up 200% from $0.05; Adjusted EBITDA $26.6M (+12.9%) with margin 19.2%.
- Organic revenue growth 8.2% led by Pain Treatments (+6.4%) and Surgical Solutions (+9.3%).
- Cash from operations $30.1M, +192% YoY; reaffirms FY2025 revenue $560-570M and Adj. EBITDA $112-116M.
- Entered new credit agreement with $300M term loan and $100M revolver, reducing annual interest by ~$2M.

## SEC filing metadata
- accession: 0001665988-25-000025
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000166598825000025/0001665988-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000166598825000025/bvs-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001665988-25-000025
- JSON: https://secwatch.observer/filing/0001665988-25-000025.json
- Plain text: https://secwatch.observer/filing/0001665988-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.